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study demonstrated high tumor-to-blood ratios (6.2 ± 0.9 
and 6.9 ± 1.0, for DU-145 and MCF-7, respectively, at 
4 h after injection). Renal radioactivity concentration 
was 16-fold lower for 99mTc-ZIGF1R:4551-GGGC than for 
[99mTc(CO)3]+-(HE)3-ZIGF1R:4551 at 4 h after injection. 
However, the liver uptake of 99mTc-ZIGF1R:4551-GGGC was 
1.2- to 2-fold higher in comparison with [99mTc(CO)3]+-
(HE)3-ZIGF1R:4551. A possible reason for the elevated hepatic 
uptake of 99mTc-ZIGF1R:4551-GGGC is a high lipophilicity of 
amino acids in the binding site of ZIGF1R:4551, which is not 
compensated in 99mTc-ZIGF1R:4551-GGGC. In conclusion, 
99mTc-ZIGF1R:4551-GGGC can visualize the IGF-1R expres-
sion in human tumor xenografts and provides low retention 
of radioactivity in kidneys. Further development of this 
imaging agent should include molecular design aimed at 
reducing the hepatic uptake.
Keywords Affibody molecule · IGF-1R · Peptide-based 
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Introduction
The insulin-like growth factor-1 receptor (IGF-1R) is a 
dimeric transmembrane tyrosine kinase receptor, which 
is activated by two ligands, insulin-like growth factor-1 
(IGF-1) or insulin-like growth factor-2 (IGF-2). Binding of 
IGF-1 and IGF-2 is followed by signaling through several 
different intracellular pathways, leading to an increased 
rate of cellular proliferation and unresponsiveness to 
apoptotic signals (Dearth et al. 2007; Chitnis et al. 2008; 
Baserga 2009).
For several types of cancer, an abnormally high expres-
sion level of IGF-1R is associated with metastasis and 
resistance to therapy (Pollak et al. 2004; Werner and 
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Bruchim 2009; LeRoith and Roberts 2003). Therefore, 
IGF-1R is considered as a therapeutic target in the treat-
ment of breast (Guvakova and Surmacz 1997; Turner et al. 
1997), prostate (Hellawell et al. 2002), lung (Ouban et al. 
2003), colorectal (Hakam et al. 1999), endometrial and 
bladder carcinomas, melanomas, and sarcomas (Khand-
wala et al. 2000). The main therapeutic approaches directed 
against IGF-1R signaling include the use of anti-receptor 
monoclonal antibodies, ligand-neutralizing monoclonal 
antibodies, and tyrosine kinase inhibitors (Pollak 2012; 
Haisa 2013; Karamouzis and Papavassiliou 2012; Sachdev 
and Yee 2007). All these approaches are highly specific, 
and the success depends on pre-selecting the patients that 
have IGF-1R-expressing tumors and would therefore most 
likely respond to IGF-1R-therapies (Carden et al. 2009). Of 
equal importance is to exclude the potential non-responders 
in order to avoid overtreatment. Therefore, robust methods 
to determine IGF-1R expression status, both initially and as 
a consequence of treatment are necessary.
Currently, the most common and established method for 
detection of molecular targets in tumors is biopsy sampling 
followed by immunohistochemistry, enzyme-linked immu-
nosorbent assay (ELISA), fluorescent in situ hybridization 
(FISH), or other assays. A drawback with these methods 
is that expression heterogeneity in the tumor might lead to 
false-negative findings. Moreover, the IGF-1R expression 
might change during the course of disease, which might 
necessitate multiple biopsies.
Radionuclide molecular imaging of molecular target 
expression allows repeated non-invasive investigation of 
receptor status at different time points and reduces possi-
bility of errors caused by target expression heterogeneity 
(Tolmachev et al. 2010a). However, radionuclide molecular 
imaging of IGF-1R is challenging because of its expres-
sion in normal tissues and the relatively low expression 
level usually found in tumors (10,000–30,000 receptors 
per cell). The use of radiolabeled therapeutic anti-IGF-1R 
monoclonal antibodies is a straightforward approach for 
the development of agents for the visualization of IGF-
1R expression in tumors. A monoclonal antibody R1507, 
labeled with 111In or 89Zr, was found to allow imaging of 
IGF-1R-expressing SUM149 breast cancer xenografts 
in mice (Heskamp et al. 2010). The probe showed spe-
cific uptake in tumors, but the long blood residence time 
resulted in high background (tumor-to-blood ratio of 
3.8 ± 0.3) and delayed imaging time (3–7 days p.i.) (Hes-
kamp et al. 2010). Despite these limitations, it was found 
that 111In-labeled R1507 could predict the response to ther-
apy in a bone sarcoma model (Fleuren et al. 2011). The use 
of F(ab′)2 and Fab fragments of R1507 demonstrated that 
a higher imaging contrast can be achieved at earlier time 
points (Heskamp et al. 2012; Fleuren et al. 2013). These 
studies suggested that a reduction of the size of the probe 
is a promising approach for improving contrast (and there-
fore, sensitivity) of IGF-1R imaging. An important precon-
dition for successful imaging was retained high affinity of 
the targeting agent.
Affibody molecules are a class of non-immunoglobulin-
based imaging agents that are characterized by small size, 
high affinity, and specificity for their intended target. They 
are engineered scaffold proteins derived from one of the 
independently folding domains of staphylococcal protein 
A (Nygren 2008; Löfblom et al. 2010). The affibody mol-
ecules are only 58 amino acids long (Mw 6–7 kDa), they are 
robust and devoid of cysteine residues in the framework. 
They typically fold into anti-parallel three-helix bundles. 
The affibody molecules are characterized by an efficient 
extravasation and rapid biodistribution, and their small size 
allows for a rapid clearance of unbound probe from blood 
and healthy tissues. For many targets, affibody molecules 
with high affinity (low nanomolar or subnanomolar) have 
been generated, which prevents rapid washout from the 
tumor (Ahlgren and Tolmachev 2010). Achieving high con-
centrations of tracer in the tumor and low concentrations 
in other tissues results in high imaging contrast, which is 
crucial for imaging sensitivity. An additional advantage 
of the rapid in vivo kinetics of affibody molecules is that 
short-lived radionuclides can be used and imaging can be 
performed shortly after injection (Ahlgren and Tolmachev 
2010).
The feasibility of radionuclide molecular imaging of 
IGF-1R-expressing xenografted tumors was demonstrated 
earlier, using the 111In-H6-DOTA-ZIGF1R:4551 affibody 
molecule (Tolmachev et al. 2012a). The probe was found 
to crossreact with murine IGF-1R, which makes mice an 
adequate model reflecting all interactions of the imag-
ing agent. Tumor visualization was possible shortly after 
injection (4–8 h). However, the study has shown a high 
uptake in liver and spleen. The aforementioned feasibil-
ity study was performed using a construct containing an 
N-terminal hexahistidine tag. Experience using HER2-
targeting affibody molecules indicated the presence of 
hexahistidine tag at N-terminus to be associated with ele-
vated hepatic uptake (Ahlgren et al. 2008, 2009), while 
the use of a glutamate-containing tag with the amino acid 
sequence HEHEHE permitted an appreciable reduction of 
radioactivity uptake in the liver (Tolmachev et al. 2010b; 
Hofström et al. 2011). We have shown that a high hydro-
philicity and negative charge of the HEHEHE-tag play 
a major role in balancing a positive charge and elevated 
lipophilicity of [99mTc(CO)3]+ and in reduction of hepatic 
uptake of [99mTc(CO)3]+-labeled anti-HER2 affibody mol-
ecules (Hofström et al. 2013). Consequently, the introduc-
tion of a HEHEHE-tag at the N-terminus of the anti-IGF-
1R affibody molecule resulted in a significantly lower liver 
uptake for [99mTc(CO)3]+-(HE)3-ZIGF1R:4551 compared to 
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111In-H6-DOTA-ZIGF1R:4551 (Orlova et al. 2013). However, 
the radioactivity uptake in the liver remained higher than 
the uptake in tumor. Furthermore, renal retention of residu-
alizing 111In-DOTA and [99mTc(CO)3]+-HEHEHE labels 
was also high. Even though renal metastases are uncom-
mon, high renal uptake might complicate the detection of 
metastases in the lumbar region.
Multiple studies have previously demonstrated that 
internalization of affibody molecules by cancer cells after 
binding to an overexpressed receptor is rather slow, 20–
30 % of cell-bound tracer per day (Ahlgren et al. 2008, 
2009; Wållberg et al. 2011; Tolmachev et al. 2012a; Orlova 
et al. 2013). The same pattern was also observed for IGF-
1R-binding affibody molecules in previous studies (Tol-
machev et al. 2012a; Orlova et al. 2013). For this reason, 
residualizing properties of labels are not critical for tumor 
uptake shortly after injection. On the opposite, interaction 
of affibody molecules with scavenger receptors in excre-
tory organs (kidneys and liver) leads to rapid internaliza-
tion, transfer into lysosomal compartment and degradation. 
Radiocatabolites of non-residualizing labels “leak” rapidly 
from hepatocytes and proximal tubuli cells, while residual-
izing labels got trapped intracellularly. As a result, reten-
tion of residualizing labels is much higher than retention of 
non-residualizing ones in liver and, especially, in kidneys 
(Hofström et al. 2011; Tolmachev et al. 2009). Thus, the 
use of non-residualizing labels may, in principle, reduce 
uptake of affibody-delivered radioactivity in excretory 
organs without compromising uptake in tumors.
Wållberg et al. (2011) demonstrated previously that 
the use of a GGGC sequence at the C-terminus of an anti-
HER2 affibody molecule as a peptide-based chelator for 
99mTc provided an efficient labeling. The label was stable 
in murine plasma in vitro. High in vivo stability of 99mTc-
GGGC-complex was also confirmed by experiments with 
anti-HER2 affibody molecule (Wållberg et al. 2011), which 
demonstrated low uptake of radioactivity in stomach and 
salivary gland. In the case of complex instability, relased 
99mTc-pertechnetate accumulates in these organs (Zuckier 
et al. 2004). Importantly, it was found that 99mTc-GGGC-
complex is a non-residualizing label, providing a high 
uptake in the tumor but low uptake in liver and kidneys. 
However, due to the limited experience using affibody mol-
ecules, it was unknown if the findings for HER2-targeting 
affibody molecules can be directly translated to affibody 
molecules for imaging of other targets.
The goal of the current study was to evaluate if labeling 
of the anti-IGF-1R affibody molecule ZIGF1R:4551, contain-
ing the peptide-based chelator GGGC at the C-terminus, 
with 99mTc would provide a reduction of radioactive uptake 
in the excretory organs, and thereby improve imaging 
contrast. The best previous variant, [99mTc(CO)3]+-(HE)3-
ZIGF1R:4551, was used for head-to-head comparison.
Materials and methods
Materials
99mTc was obtained as pertechnetate (99mTcO4−) from an 
Ultra-Technekow™ DTE Technetium Generator (Covi-
dien), using 0.9 % sterile sodium chloride (Covidien) as 
generator eluent. Buffers, including 0.05 M phosphate buff-
ered saline pH 7.4, and PBS containing 2 % BSA, were 
produced in house. α-d-gluconic acid sodium salt and eth-
ylenediaminetetraacetic acid (EDTA) were purchased from 
Sigma-Aldrich, tin(II) chloride dihydrate (SnCl2 × 2H2O) 
was obtained from Fluka Chemika. Human recombinant 
IGF-1R was purchased from BioVision Inc. 125I was pur-
chased from PerkinElmer (Waltham, MA, USA). Organic 
solvents were purchased from Merck (Darmstadt, Ger-
many). Chloramine-T (CAT) and sodium metabisulfite 
were from Sigma Chemical Company (St. Louis, MO). 
The measuring of the radioactivity was performed using 
an automated gamma spectrometer equipped with a 3-in. 
NaI(Tl) detector (1480 WIZARD; PerkinElmer). Yield 
and radiochemical purity of the labeled affibody con-
structs were analyzed using instant thin-layer chromatog-
raphy (ITLC) strips (150-771 DARK GREEN, Tec-Control 
Chromatography strips from Biodex Medical Systems). 
NuPAGE 10 % Bis–Tris gels (Life Technologies) were 
used for analysis of conjugates and for in vitro stability 
studies. The distribution of radioactivity along ITLC strips 
and SDS-PAGE gels was measured on a Cyclone™ Storage 
Phosphor System (PerkinElmer). The binding affinity tests 
were performed using a LigandTracer Yellow instrument 
provided by Ridgeview Instruments AB. An unpaired t test 
was used to determine significant differences (p < 0.05) in 
all experiments.
Protein production
The gene encoding ZIGF1R:4551 (Tolmachev et al. 2012a) was 
PCR amplified and inserted into the plasmid pET21a(+) 
(Novagen) using the restriction enzymes NdeI and Hin-
dIII. The oligonucleotides used gave an expression cassette 
with the amino acid sequence M-ZIGF1R:4551-GGGC under 
control of the T7-promoter. The protein was expressed in 
Escherichia coli strain BL21(DE3)(Novagen) at 37 °C 
after induction by Isopropyl β-d-1-thiogalactopyranoside 
to a final concentration of 1 mM at OD600 = 0.8. Cells 
were grown in a 500-mL shake flask culture with Tryptic 
soy broth (Merck) supplemented with 5 g/L yeast extract 
(Merck) as medium. Production was performed for 3 h, 
after which the cells were harvested by centrifugation and 
frozen. On the following day, the cell pellet was thawed 
and resuspended in 30 mL deionized water after which the 
cells were broken by sonication. Cell debris was pelleted 
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by centrifugation and the cleared lysate was recovered and 
heat treated at 70 °C for 10 min after which the formed 
precipitate was removed by centrifugation. The lysate was 
subsequently filtered through a 0.45-μm filter; potentially 
formed disulphide bridges were reduced followed by sepa-
ration by reversed-phase HPLC (RP-HPLC) as described 
(Orlova et al. 2013).
The purity of ZIGF1R:4551-GGGC was determined by RP-
HPLC as previously described (Tolmachev et al. 2010b). 
ZIGF1R:4551-GGGC was analyzed by electrospray ionization 
mass spectrometry (ESI MS) to confirm its authenticity as 
previously described (Tolmachev et al. 2010b).
Labeling and stability test
Site-specific radiolabeling with technetium-99 m was per-
formed using lyophilized kits. Each kit contained 5 mg of 
sodium a-d-glucoheptonate dihydrate, 100 μg of edetate 
disodium (Na2EDTA), and 75 μg of tin(II)chloride dihy-
drate (SnCl2 × 2H2O) as has been optimized earlier for 
anti-HER2 affibody molecules by Ahlgren et al. (2010). 
The content of the freeze-dried kit was dissolved in 100 μL 
degassed PBS and added to the vial containing 100 μg 
ZIGF1R:4551-GGGC. After adding 100 μL 99mTcO4−, the 
reaction vial was filled with argon gas to protect the mix-
ture from oxidation, then thoroughly vortexed and incu-
bated for 2 h (95 °C). After cooling down for 15 min, the 
labeling yield was determined by ITLC. PBS was used as 
mobile phase for analysis of the labeling efficiency. In this 
system, the proteins and colloids stay on application point, 
while unbound radioactivity moves with the front. Purifi-
cation was performed by size-exclusion chromatography 
using disposable NAP-5 columns (GE Healthcare), which 
were pre-equilibrated and eluted with PBS containing 
2 % BSA. The stability in serum was analyzed by mixing 
murine serum (200 μL) with 10 μL freshly labeled 99mTc-
ZIGF1R:4551-GGGC. The samples were incubated for 1 h at 
37 °C. As control, 10 μL freshly labeled 99mTc-ZIGF1R:4551-
GGGC was mixed with 200 μL PBS containing 2 % BSA 
and incubated for 1 h at r.t. All samples were analyzed by 
both ITLC and sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) using MES–SDS buffer at 
210 V constant. A sample of 99mTc-pertechnetate was used 
as reference standard for low molecular weight compounds.
For radioiodination of the natural ligand, 20 µg of IGF-1 
(1 mg/mL in PBS) was mixed with 20 MBq of 125I, and the 
mixture additionally buffered with 40 µL PBS. The elec-
trophilic iodination was initiated by adding 10 µg chlora-
mine-T (1 mg/mL in PBS). After 1 min, the reaction was 
quenched by adding 20 µg sodium metabisulfite (1 mg/
mL in PBS), and 125I-IGF-1 was purified by size-exclusion 
chromatography using disposable NAP-5 column.
Cell culture
Human prostate cancer (DU-145) and breast cancer (MCF-
7) cell lines (ATCC, purchased via LGC Promochem) were 
used for binding specificity and cellular processing studies. 
The IGF1R expression in these cell lines was documented 
earlier (Li et al. 2013; Turney et al. 2012). Roswell Park 
Memorial Institute medium (RPMI) was used to culture all 
cell lines. The cells were counted using an electronic cell 
counter (Beckman Coulter).
In vitro characterization
The in vitro binding specificity tests were designed to 
determine if the binding of 99mTc-ZIGF1R:4551-GGGC to 
IGF-1R-expressing cells (MCF-7 and DU-145) was satu-
rable and therefore receptor mediated. A cross blocking 
of ZIGF1R:4551-GGGC and IGF-1 was evaluated. In the first 
set of experiments, saturation of 125I-IGF-1 binding was 
tested. For each cell line, a group of nine Petri dishes was 
used. Each Petri dish contained a cell monolayer of ca. 
7 × 105 cells/dish. Cells in three of the six Petri dishes 
were pre-saturated with 500 μL blocking solution contain-
ing 20 mM unlabeled ZIGF1R:4551-GGGC. Cells in another 
three dishes were saturated with 500 μL blocking solution 
containing 20 mM unlabeled IGF-1. To the remaining three 
Petri dishes, 500 μL complete RPMI medium was added 
in order to obtain the same volume. Five minutes later, 
500 μL of a solution containing 5 nM of 125I-IGF-1 was 
added to each dish, followed by incubation during 1.5 h at 
37 °C under 5 % CO2. After the incubation, the media were 
collected, the cells were washed with incomplete medium, 
500 μL trypsin–EDTA solution was added, and the cells 
were incubated for 10 min. The detached cells were diluted 
in 500 μL complete media, resuspended, and transferred to 
the appropriate fraction tubes. The radioactivity of media 
and cells was measured using an automated gamma coun-
ter and the percent of cell-bound radioactivity was calcu-
lated. In the second set of experiments, saturation of 99mTc-
ZIGF1R:4551-GGGC was tested. The protocol was similar to 
the previous one, but the concentration of blocking solu-
tions was 5 mM.
For internalization studies, cells (750,000 per dish) were 
incubated with the labeled compound (1.5 nM) at 37 °C, 
5 % CO2. At predetermined time points (1, 2, 4, 8, and 24 h 
after incubation start), the medium from a set of 3 dishes 
was removed. To collect the membrane-bound radioactiv-
ity, the cells were treated with 0.2 M glycine buffer contain-
ing 4 M urea, pH 2.5, for 5 min on ice, and the acid fraction 
was collected. Cells containing internalized radioactivity 
were detached by treatment with 1 M NaOH at 37 °C for 
0.5 h and collected. The percentage of membrane-bound 
307Evaluation of 99mTc-ZIGF1R:4551-GGGC affibody molecule
1 3
and internalized radioactivity was calculated for each time 
point.
The affinity was measured using a LigandTracer Instru-
ment (Ridgeview Instruments AB) at room temperature, 
as previously described (Björkelund et al. 2011). Briefly, 
a Petri dish (Nunclon, diameter 100 mm, containing 3 mL 
culture medium) with DU-145 cells was attached to the 
rotating table of the instrument. After 10 min baseline 
run, 99mTc-ZIGF1R:4551-GGGC was added to the medium 
to obtain a ligand concentration of 0.3 nM, and the uptake 
curve was recorded for 150 min. Thereafter, the ligand 
concentration was increased to 0.9 nM, and the uptake 
curve was recorded for another 140 min. The final uptake 
measurement was performed with 99mTc-ZIGF1R:4551-
GGGC 1.8 nM concentration for 140 min. Then the 99mTc-
ZIGF1R:4551-GGGC-containing medium was aspirated, 3 mL 
of fresh medium was added, and the dissociation curve was 
measured. Interaction analysis and calculation of equilib-
rium dissociation constant (KD) were performed with Trac-
erDrawer software (Ridgeview Instruments AB). Four addi-
tional measurements were performed at 4 °C to exclude the 
influence of ligand internalization.
In vivo studies
The animal study was planned and performed in accord-
ance with national legislation on protection of laboratory 
animals and was approved by the Ethics Committee for 
Animal Research in Uppsala.
For tumor grafting, 5 × 106 prostate cancer DU-145 
cells (in Matrigel, BD Biosciences) were subcutaneously 
implanted in the right hind leg of male Balb/c nu/nu mice. 
Xenografts were allowed to grow for 2 weeks. At the time 
of experiment, the animal weight was 21.5 ± 1.6 g, and 
the tumor weight was 290 ± 170 mg. Before implanta-
tion of the breast cancer MCF-7 cells, female Balb/c nu/nu 
mice were pre-implanted with estradiol pellets (0.5 mg/d, 
21 days; Innovative Research of America). The cells, 
5 × 106 in Matrigel, were implanted in the right hind leg 
2 weeks before experiment. At the time of experiment, the 
animal weight was 20.5 ± 0.8 g, and the tumor weight was 
60 ± 30 mg. Immediately before experiments, the tumor-
bearing mice were randomized in groups containing four 
animals each.
The animals (four mice per data point) were injected 
intravenously with 60 kBq of radiolabeled conjugate per 
mouse in 100 μL PBS. The protein dose was adjusted to 
1 µg per mouse by addition of non-labeled ZIGF1R:4551-
GGGC. The mice were sacrificed at predetermined time 
points by an intraperitoneal injection of anesthesia, Ket-
alar–Rompun solution (20 μL/g body weight; Ketalar, 
10 mg/mL; Rompun, 1 mg/mL). Blood, lung, liver, spleen, 
stomach, kidney, salivary gland, tumor, samples of colon, 
pancreas, muscle, bone, as well as the rest of intestines 
with their content were collected. Organs and tissue sam-
ples were weighed, and their radioactivity was measured. 
The tissue uptake values were calculated as percent of 
injected activity per gram tissue (%IA/g).
To evaluate in vivo kinetics, the biodistribution of 99mTc-
ZIGF1R:4551-GGGC was measured in mice bearing DU-145 
xenografts at 1, 4, and 8 h after injection. To verify speci-
ficity of in vivo targeting, the effect of in vivo receptor 
saturation was tested. For this purpose, one group of mice 
was injected in 60 kBq of 99mTc-ZIGF1R:4551-GGGC, the 
protein dose being adjusted to 40 µg per mouse using non-
labeled ZIGF1R:4551-GGGC. This group was euthanized at 
4 h after injection. For direct comparison, another group 
of tumor-bearing mice was injected with 60 kBq (1 µg) of 
[99mTc(CO)3]+-(HE)3-ZIGF1R:4551, and the biodistribution 
was measured at 4 h after injection.
In addition, the biodistribution of 99mTc-ZIGF1R:4551-
GGGC and [99mTc(CO)3]+-(HE)3-ZIGF1R:4551 was compared 
at 4 h after injection of 60 kBq (1 µg) in female Balb/c nu/
nu mice bearing MCG-7 breast cancer xenografts. The goal 
was to confirm the in vivo data using different types of 
tumors (breast vs prostate cancer) as well as possible dif-
ferences attributed to sex (female vs male).
To obtain a visual confirmation of biodistribution data, 
one mouse with a DU-145 xenograft and one mouse with 
a MCF-7 xenograft were injected with 99mTc-ZIGF1R:4551-
GGGC (1 MBq, 1 μg, in 100 μL PBS) and imaging was 
performed 4 h later. Immediately before imaging, the ani-
mals were killed by an overdose of anesthetics. Imaging 
was performed using a GE Infinia gamma camera equipped 
with a low-energy high-resolution collimator. Static images 
(30 min) were obtained with a zoom factor of 2 in a 
256 × 256 matrix. The images were evaluated using Osi-
ris 4.19 software (University Hospital of Geneva, Switzer-
land). In each animal, a region of interest was drawn around 
the tumor. The same region was copied to the contralateral 
thigh. Tumor-to-contralateral thigh ratios were calculated 
based on average counts in the regions of interest.
Results
Production and labeling
The IGF-1R targeting affibody molecule, ZIGF1R:4551-GGGC, 
was expressed in Escherichia coli and purified by heat 
treatment followed by reversed-phase high-performance 
liquid chromatography (Fig. 1). The ESI MS confirmed 
authenticity of ZIGF1R:4551-GGGC as the deconvoluted mass 
(6297.0 Da) was in an excellent agreement with the theoreti-
cal molecular mass of 6297.0 Da. According to HPLC analy-
sis, a purity of ZIGF1R:4551-GGGC was more than 99.5 %.
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ZIGF1R:4551-GGGC was successfully labeled with 99mTc, 
with a resulting yield of 96.9 ± 2.9 %. The purification was 
performed using disposable size-exclusion NAP-5 columns, 
and the resulting radiochemical purity was 99.8 ± 0.4 %. 
A serum stability test revealed very good serum stability 
after 1 h incubation at 37 °C. The ITLC results showed 
97.2 ± 1.7 % stability, while the SDS-PAGE analysis 
showed no measurable release of radionuclide from sam-
ples incubated in serum (see Fig. 2). The only observed 
radioactivity peaks corresponded to the migration path of 
the ZIGF1R:4551-GGGC affibody molecule. There was no 
observed aggregation of affibody molecules or transchela-
tion of radionuclide to blood plasma proteins. Similarly, the 
stability in PBS was also high as shown in Fig. 2.
In vitro characterization
The results of in vitro binding specificity test are presented 
in Fig. 3. A pre-saturation of receptors by adding a large 
molar excess of unlabeled affibody molecules or a natural 
IGF-1R ligand, IGF-1, caused significant (p < 0.05) reduc-
tion of 99mTc-ZIGF1R:4551-GGGC uptake in IGF-1R-express-
ing DU-145 and MCF-7 cells (Fig. 3a). In addition, a large 
molar excess of non-labeled ZIGF1R:4551-GGGC reduced 
significantly binding of radiolabeled natural ligand, 125I-
IGF-1, to these cell lines (Fig. 3b). This demonstrated that 
99mTc-ZIGF1R:4551-GGGC could bind specifically to IGF1R 
and suggested that the affibody molecule has the same or 
an overlapping binding site as the natural ligand.
Data concerning internalization of 99mTc-ZIGF1R:4551-
GGGC by DU-145 and MCF-7 cells are presented in 
Fig. 4a and b. The internalization pattern by both cell 
lines was similar, showing a relatively low fraction of 
internalized radioactivity. Although a gradual increase of 
the internalized fraction was observed for both cell lines, 
only 18.3 ± 0.8 % of the total cell-associated radioactiv-
ity were internalized at 24 h after incubation start for DU-
145 and 16.2 ± 0.6 % for MCF-7 cells. The binding affin-
ity of 99mTc-ZIGF1R:4551-GGGC to DU-145 cells was also 
measured. Similar to a previous study (Orlova et al. 2013), 
the interaction did not follow a 1:1 Langmuir adsorption 
model and was found to be a combination of two independ-
ent processes when subjected to an Interaction Map analy-
sis (Fig. 5). The Interaction Map shows the two processes 
where the higher affinity interaction is 844 pM and the 
lower affinity interaction is 12 nM.
Biodistribution in tumor-bearing mice
Data concerning biodistribution of 99mTc-ZIGF1R:4551-
GGGC in Balb/c nu/nu mice bearing DU-145 prostate can-
cer xenografts (injected dose 1 µg) as a function of time are 
present in Table 1 and Figs. 6 and 7.










Fig. 1  SDS-PAGE analysis of samples taken during the purification 
of ZIGF1R:4551-GGGC. Lane 1 sample after cell lysis and initial clarifi-
cation, lane 2 sample after heat treatment, lane 3 sample after HPLC 
purification
Fig. 2  SDS-PAGE analysis of 99mTc-ZIGF1R:4551-GGGC stability in 
serum. Distribution of radioactivity along lanes was visualized using 
Cyclone™ Storage Phosphor System. The signal was measured as 
digital light units (DLU) and was proportional to the radioactivity in 
given point of the SDS-PAGE gel. 1 99mTc-ZIGF1R:4551-GGGC sam-
ple, which was incubated in murine serum at 37 °C for 1 h. 2 99mTc-
ZIGF1R:4551-GGGC sample, which was incubated in PBS at 37 °C for 
1 h. 3 99mTc-pertechnetate was used as a marker for low molecular 
weight compounds
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The data in Table 1 show that the tumor uptake at 
4 h after injection of 40 µg of 99mTc-ZIGF1R:4551-GGGC 
(0.5 ± 0.1 %IA/g) was significantly (p < 0.05) lower than 
the uptake after injection of 1 µg (0.9 ± 0.1 %IA/g). More-
over, there was a significantly lower uptake in IGF-1R-ex-
pressing tissues, such as lung, pancreas, stomach, colon, 
Fig. 3  In vitro specificity test of ZIGF1R:4551-GGGC binding to IGF-
1R on DU-145 (human prostate cancer) and MCF-7 (human breast 
cancer) cell lines. a Pre-saturation of receptors with unlabeled 
ZIGF1R:4551 or IGF-1 caused significant (p < 0.05 in Student’s t test) 
reduction of cell-bound 99mTc-ZIGF1R:4551-GGGC radioactivity, b pre-
saturation of receptors with unlabeled ZIGF1R:4551 or IGF-1 caused sig-
nificant (p < 0.05 in Student’s t test) reduction of cell-bound 125I-IGF 
radioactivity
Fig. 4  Binding and internaliza-
tion of 99mTc-ZIGF1R:4551-GGGC 
at 37 °C by prostate cancer 
DU-145 (a) and breast cancer 
MCF-7 (b) cells. Data are 
normalized to a maximum 
cell-bound radioactivity and 
presented as average value from 
3 cell dishes ± SD. Error bars 
might not be seen because they 
are smaller than point symbols
Fig. 5  Interaction map: interac-
tion between 99mTc-ZIGF1R:4551-
GGGC and DU-145 cells. The 
two simultaneous interactions 
observed as distinct processes in 
the map. The grey scale reflects 
contribution of a process, where 
darker areas represent larger 
contributions
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and salivary glands after injection of saturating amount 
of unlabeled ZIGF1R:4551-GGGC together with 99mTc-
ZIGF1R:4551-GGGC. This demonstrates the saturable char-
acter of the binding of tracer to IGF-1R also in vivo and 
suggests its specificity.
The biodistribution of the conjugate was characterized 
by rapid clearance from blood and normal tissues (Fig. 6). 
A low accumulation of radioactivity in the intestines with 
their content (3.7 ± 0.6 %IA at 1 h after injection and 
3.2 ± 1.3 %IA at 4 h) indicated that hepatobiliary excretion 
played a minor role in the clearance. The clearance was, 
most likely, predominantly renal. However, the retention 
of radioactivity in kidneys was low with a rapid decrease 
between time points (15 ± 2, 7.5 ± 0.7 and 4.9 ± 0.8 %IA/g 
at 1, 4, and 8 h after injection, respectively), indicating a 
non-residualizing character of the label. The high initial 
uptake of radioactivity in the liver (11 ± 2 %IA/g) was fol-
lowed by an appreciable decrease reaching 4.1 ± 0.1 %IA/g 
at 4 h after injection and 2.33 ± 0.8 %IA/g at 8 h. The 
release of radioactivity from the tumor (1.8-fold decrease 
at 4 h after injection compared to 1 h) was slower than the 
clearance from blood (3.6-fold between these time points) 
and release from liver (2.7-fold).
Tumor-to-organ ratios are presented in Fig. 7. There 
was a significant (p < 0.05) increase of tumor-to-blood and 
tumor-to-liver ratios between 1 and 4 h after injection but 
no significant increase in tumor-to-organ ratios between 4 
and 8 h after injection. This indicates that 4 h after injection 
could be an optimal imaging time.
The imaging potential of 99mTc-ZIGF1R:4551-GGGC 
was further investigated by comparing its biodistribution 
with the biodistribution of the previously developed IGF-
1R-interacting probe [99mTc(CO)3]+-(HE)3-ZIGF1R:4551. 
Data concerning the comparative biodistribution in mice 
bearing DU-145 and MCF-7 xenografts are present in 
Table 2. The comparison of tumor-to-organ ratios is shown 
in Table 3. The influence of labeling approach on biodis-
tribution was very similar in both models. Noticeably, 
there was a significantly (p < 0.001) faster blood clear-
ance for 99mTc-ZIGF1R:4551-GGGC in both male and female 
mice. The accumulation of radioactivity in the kidneys 
was appreciably different for the two compounds, where 
99mTc-ZIGF1R:4551-GGGC was found to give a 15- to 17-fold 
lower renal uptake compared to [99mTc(CO)3]+-(HE)3-
ZIGF1R:4551. Uptake of [99mTc(CO)3]+-(HE)3-ZIGF1R:4551 in 
liver and spleen was lower in both cases. The higher liver 
uptake of 99mTc-ZIGF1R:4551-GGGC was not associated 
Table 1  Specificity of targeting of IGF-1R in vivo
Biodistribution (4 h after injection) of 99m Tc-ZIGF1R:4551-GGGC 
in Balb/c nu/nu mice bearing IGR-1R-expressing DU-145 prostate 
cancer xenografts injected with 1 or 40 μg protein. Uptake of 99mTc-
ZIGF1R:4551-GGGC in tumors and IGF-1R-expressing organs (lung, 
pancreas, stomach, and colon) was significantly lower in animals 
injected with higher dose of ZIGF1R:4551-GGGC
The data are expressed as %IA/g and represent the average value 
from 4 animals ± standard deviation
* Significant difference (p < 0.05) in uptake between mice injected 
with 1 and 40 μg protein
1 µg 40 µg
Blood 0.14 ± 0.01* 0.22 ± 0.04
Lung 1.19 ± 0.06* 0.61 ± 0.05
Liver 4.08 ± 0.1 2.85 ± 1.3
Spleen 3 ± 0.6 3.13 ± 2.4
Pancreas 0.98 ± 0.1* 0.33 ± 0.06
Stomach 1.04 ± 0.3* 0.48 ± 0.05
Colon 1.5 ± 0.4* 0.7 ± 0.4
Kidney 7.5 ± 0.7 6.4 ± 0.5
Salivary gland 1.6 ± 0.1* 1.0 ± 0.1
Tumor 0.9 ± 0.1* 0.5 ± 0.1
Muscle 0.27 ± 0.01 0.26 ± 0.1
Bone 0.63 ± 0.1 0.43 ± 0.1
Fig. 6  Biodistribution of 99mTc-ZIGF1R:4551-GGGC in Balb/c nu/nu 
mice with subcutaneous DU-145 prostate cancer xenografts as a func-
tion of time. Data are presented as an average %IA/g and standard 
deviation for four mice
Fig. 7  Tumor-to-organ ratios of 99mTc-ZIGF1R:4551-GGGC in Balb/c 
nu/nu mice with subcutaneous DU-145 prostate cancer xenografts. 
Data are presented as an average value and standard deviation for 
four mice
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with a high hepatobiliary excretion. The levels of radioac-
tivity in the intestines with content for 99mTc-ZIGF1R:4551-
GGGC reached 3.15 ± 1 %IA and 3.14 ± 0.25 %IA for 
male and female mice, respectively, while the correspond-
ing values for [99mTc(CO)3]+-(HE)3-ZIGF1R:4551 were 
6.41 ± 0.4 %IA/g and 4.68 ± 1 %IA/g. The tumor uptake 
was similar for both compounds in mice bearing MCF-7 
xenografts, but the tumor uptake of 99mTc-ZIGF1R:4551-
GGGC in DU-145 xenografts was significantly lower than 
the uptake of [99mTc(CO)3]+-(HE)3-ZIGF1R:4551.
Tumor-to-blood ratios were higher for 99mTc-ZIGF1R:4551-
GGGC in both models (Table 3), while tumor-to-liver, 
tumor-to-spleen, and tumor-to-pancreas ratios were signifi-
cantly higher for [99mTc(CO)3]+-(HE)3-ZIGF1R:4551.
Gamma camera imaging showed that 99mTc-ZIGF1R:4551-
GGGC was capable of visualizing subcutaneous IGF-
1R-expressing DU-145 and MCF-7 xenografts (Fig. 8). 
From this image, the tumor-to-contralateral site ratio 
was determined to 3.3 for MCF-7 and 3.9 for DU-145. 
The image also indicated the feasibility of detecting 
Table 2  Comparative biodistribution of 99mTc-ZIGF1R:4551-GGGC and [99mTc(CO)3]+-(HE)3-ZIGF1R:4551 in mice bearing DU-145 and MCF-7 
xenografts at 4 h after injection
The data are expressed as %IA/g and present the average value from 4 animals ± standard deviation
* Significant difference (p < 0.05) between the uptake of 99mTc-ZIGF1R:4551-GGGC and [99mTc(CO)3]+-(HE)3-ZIGF1R:4551 Affibody molecules in 
mice bearing DU-145 and MCF-7 xenografts
DU-145 MCF-7
99mTc-ZIGF1R:4551-GGGC [99mTc(CO)3]+-(HE)3-ZIGF1R:4551 99mTc-ZIGF1R:4551-GGGC [99mTc(CO)3]+-(HE)3-ZIGF1R:4551
Blood 0.14 ± 0.01* 0.47 ± 0.03 0.2 ± 0.07* 0.36 ± 0.04
Lung 1.19 ± 0.07* 2.02 ± 0.5 1.6 ± 0.3 1.6 ± 0.2
Liver 4.08 ± 0.1* 3.5 ± 0.4 6.07 ± 0.1* 3.06 ± 0.4
Spleen 3.0 ± 0.6* 1.56 ± 0.2 3.11 ± 0.7* 1.43 ± 0.3
Pancreas 0.98 ± 0.1 1.13 ± 0.1 1.41 ± 0.2 1.1 ± 0.15
Stomach 1.04 ± 0.3 1.38 ± 0.2 1.44 ± 0.3 1.19 ± 0.2
Colon 1.5 ± 0.4 1.6 ± 0.2 1.4 ± 0.1 1.55 ± 0.2
Kidney 7.5 ± 0.7* 116 ± 7 9.5 ± 0.4* 164 ± 3
Sal gland 1.6 ± 0.1 1.9 ± 0.3 1.4 ± 0.2 1.2 ± 0.2
Tumor 0.9 ± 0.1* 1.3 ± 0.2 1.2 ± 0.2 1.6 ± 0.3
Muscle 0.27 ± 0.02 0.31 ± 0.06 0.29 ± 0.07 0.26 ± 0.07
Bone 0.63 ± 0.1 0.61 ± 0.15 0.59 ± 0.06 0.6 ± 0.1
Table 3  Comparison of tumor-to-organ ratios for 99mTc-ZIGF1R:4551-GGGC and [99mTc(CO)3]+-(HE)3-ZIGF1R:4551 at 4 h after injection in mice 
bearing DU-145 and MCF-7 xenografts
The data presented are average ratios together with standard deviations in four mice
* Significant difference (p < 0.05) between the tumor-to-organ ratios of 99mTc-ZIGF1R:4551-GGGC and [99mTc(CO)3]+-(HE)3-ZIGF1R:4551 Affibody 
molecules
DU-145 MCF-7
99mTc-ZIGF1R:4551-GGGC [99mTc(CO)3]+-(HE)3-ZIGF1R:4551 99mTc-ZIGF1R:4551-GGGC [99mTc(CO)3]+-(HE)3-ZIGF1R:4551
Blood 6.2 ± 0.9* 2.7 ± 0.3 6.9 ± 1.0* 4.48 ± 0.9
Lung 0.7 ± 0.1 0.7 ± 0.1 0.8 ± 0.1 0.9 ± 0.3
Liver 0.21 ± 0.02* 0.37 ± 0.05 0.20 ± 0.02* 0.5 ± 0.1
Spleen 0.3 ± 0.05* 0.8 ± 0.1 0.4 ± 0.1* 1.1 ± 0.2
Pancreas 0.9 ± 0.1* 1.13 ± 0.07 0.9 ± 0.2* 1.5 ± 0.3
Stomach 0.9 ± 0.2 0.93 ± 0.05 0.88 ± 0.05* 1.34 ± 0.3
Colon 0.6 ± 0.2 0.8 ± 0.1 0.9 ± 0.2 1.0 ± 0.2
Kidney 0.12 ± 0.01* 0.01 ± 0.001 0.13 ± 0.02* 0.01 ± 0.003
Sal gland 0.56 ± 0.01* 0.66 ± 0.07 0.91 ± 0.2 1.3 ± 0.3
Muscle 3.2 ± 0.5* 4.14 ± 0.5 4.55 ± 1.8 6.38 ± 1.65
Bone 1.4 ± 0.3* 2.2 ± 0.3 2.1 ± 0.3* 2.6 ± 0.2
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IGF-1R-expressing lung metastases. At the same time, 
radioactivity accumulation in salivary glands, kidneys, 
liver, and stomach was on the same level or higher than in 
tumors.
Discussion
Determination of IGF-1R expression level in tumors may 
yield information that can help predict response to differ-
ent treatment modalities as well as clinical outcome for 
the patient. Toward this goal, we have in this study investi-
gated a new probe, 99mTc-ZIGF1R:4551-GGGC, for determin-
ing the level of IGF-1R expression by radionuclide molec-
ular imaging in pre-clinical models of prostate and breast 
cancer. The labeling of ZIGF1R:4551-GGGC with 99mTc was 
successful, with yields exceeding 96 %. The resulting 
compound was characterized by an excellent stability with 
no signs of radionuclide release, aggregation, or a radio-
nuclide transchelation to plasma proteins (Fig. 2). These 
results are consistent with previous studies where affibody 
molecules were fitted with a GGGC peptide for 99mTc-
labeling, which showed that C-terminal positioning of the 
cysteine-containing chelators provides high stability with 
a low release of 99mTc-pertechnetate in serum due to a 
favorable geometry of the chelate (Tran et al. 2007; Wåll-
berg et al. 2011). The binding specificity test indicated that 
the binding of 99mTc-ZIGF1R:4551-GGGC to IGF-1R-ex-
pressing cell lines (human prostate cancer cells DU-145 
and human breast cancer cells MCF-7) was receptor medi-
ated (Fig. 3), suggesting that labeling has not influenced 
the ability of ZIGF1R:4551-GGGC to bind specifically to 
IGF-1R. The presence of two distinct interaction processes 
as shown by the interaction map (Fig. 5)—one with higher 
affinity (844 pM) and one with lower affinity (12 nM)—is 
consistent with previous data obtained for [99mTc(CO)3]+-
(HE)3-ZIGF1R:4551 suggesting that ZIGF1R:4551 binds to 
two binding sites on IGF-1R (Orlova et al. 2013). Since 
ZIGF1R:4551 is competing with IGF-1 for binding to the 
receptor (Li et al. 2010), a possible explanation for the 
two-process interaction may be that it binds to the receptor 
similarly as IGF-1, which has been found to interact at two 
positions on IGF-1R with negative cooperativity (Surinya 
et al. 2008). The internalization rate was relatively low for 
both DU-145 and MCF-7 cell lines, with less than 20 % of 
internalized activity after 24 h (Fig. 4). This suggested that 
the use of non-residualizing labels is feasible.
The in vivo receptor saturation experiment (Table 1) 
demonstrated a significantly lower uptake of 99mTc-
ZIGF1R:4551-GGGC in DU-145 xenografts after injection of 
a saturating dose of ZIGF1R:4551-GGGC. Together with the 
results of the in vitro specificity test, this suggests that the 
tumor uptake in vivo was receptor mediated. The uptake in 
lung, pancreas, stomach, colon, and salivary glands (i.e., 
tissues expressing IGF-1R) was also lower after injec-
tion of the saturating protein dose. Furthermore, uptake of 
affibody molecules targeting other receptors, e.g., HER2 or 
PDGFRβ, was 2- to 4-fold lower in these organs (Ahlgren 
et al. 2009; Wållberg et al. 2011; Tolmachev et al. 2014) 
than uptake of 99mTc-ZIGF1R:4551-GGGC when 1 µg was 
injected. These affibody molecules have the same scaffold 
but different amino acids involved in binding and might 
be considered as negative not-IGF-1R-binding controls 
for ZIGF1R:4551-GGGC. Uptake saturability and its signifi-
cantly higher level in comparison with uptake of not-IGF-
1R-binding counterparts indicate that the 99mTc-ZIGF1R:4551-
GGGC accumulation in these organs was also receptor 
mediated. The specific uptake in IGF-1R-expressing organs 
suggests that the murine model is adequate for in vivo stud-
ies concerning IGF-1R targeting, which is essential for 
translation of murine data to humans.
The biodistribution of 99mTc-ZIGF1R:4551-GGGC was 
characterized by fast blood clearance, which is important 
for high-sensitivity molecular imaging. The maximum 
tumor-to-blood ratios for 99mTc-ZIGF1R:4551-GGGC were 
obtained already at 4 h after injection (Fig. 7). The tumor-
to-blood ratios provided by ZIGF1R:4551-GGGC at this time 
point (6.2 ± 0.9 and 6.9 ± 1.03, for DU-145 and MCF-
7, respectively) (Table 3) were on the same level or better 
than 111In-labeled (Fab′)2-fragments of anti-IGF-1R anti-
body R1507 at 24 h after injection (7.5 ± 1.4 and 2.4 ± 0.4 
in SUM149 and EW-5 xenografts, respectively) (Heskamp 
et al. 2012; Fleuren et al. 2013). The tumor-to-blood ratios 
were also higher than the ones previously reported for anti-
IGF-1R antibody R1507 (2.8 ± 0.7) at 72 h after injection 
(Heskamp et al. 2012). Of course, such comparison should 
Fig. 8  Imaging of IGF-1R expression in DU-145 prostate cancer and 
MCF7 breast cancer xenografts in NMRI nu/nu mice using 99mTc-
ZIGF1R:4551-GGGC. Planar γ-camera images were acquired at 4 h after 
injection
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be taken very cautiously for two reasons. First, the models 
were different, which can be associated with different lev-
els of IGF-1R expression, as well as with different degree 
of vascularization and even vascular permeability. Second, 
R1507 antibody does not cross react with murine IGF-1R 
(Heskamp et al. 2012), which creates an idealized condi-
tion for this antibody and its derivatives, excluding interac-
tion with IGF-1R in normal tissues.
Previous studies, that were performed using anti-HER2 
affibody molecules, suggest that the use of a GGGC che-
lator for 99mTc at the C-terminus provides a non-residu-
alizing label (Wållberg et al. 2011). Because of the slow 
internalization of affibody molecules by cancer cells, 
this has a small effect on tumor uptake, but enables a 
substantial reduction of radioactivity retention in excre-
tory organs (kidneys and liver), where internalization 
is rapid. On the opposite, the use of the peptide chelator 
HEHEHE at the N-terminus provides a residualizing label 
for [99mTc(CO)3]+ (Tolmachev et al. 2010b). In this case, 
the retention of radionuclides in excretory organs is rather 
high, but the liver uptake is low, which is associated with 
the presence of negatively charged and hydrophilic amino 
acids (Hofström et al. 2013). Overall, this provided an 
approximately equal uptake of anti-HER2 affibody mol-
ecules in liver (0.9 ± 0.1 and 0.88 ± 0.05 %IA/g at 4 h 
after injection, for 99mTc-GGGC and [99mTc(CO)3]+-(HE)3, 
respectively), but much lower renal retention of techne-
tium-99m in the case of GGGC chelator (8.2 ± 2.9 and 
70 ± 10 %IA/g at 4 h after injection, for 99mTc-GGGC 
and [99mTc(CO)3]+-(HE)3, respectively). In this study, we 
confirmed that the clearance of 99mTc-ZIGF1R:4551-GGGC 
from kidney was rapid (Fig. 6), and renal radioactivity 
concentration was 15- to 17-fold lower than the concen-
tration of [99mTc(CO)3]+-(HE)3-ZIGF1R:4551 at 4 h after 
injection (Table 2). However, the liver uptake of 99mTc-
ZIGF1R:4551-GGGC was significantly higher than the uptake 
of [99mTc(CO)3]+-(HE)3-ZIGF1R:4551 at this time point 
(Table 2). Per se, clearance of radioactivity from liver was 
rapid (11 ± 2 vs 4.1 ± 0.1 %IA/g at 1 and 4 h, respectively) 
in the case 99mTc-ZIGF1R:4551-GGGC (Fig. 6). This was dif-
ferent from [99mTc(CO)3]+-(HE)3-ZIGF1R:4551, where reduc-
tion of hepatic activity between 1 h (2.3 ± 0.2 %IA/g) and 
4 h after injection (1.7 ± 0.3 %IA/g) was minor (Orlova 
et al. 2013). We can state that the effect of chelators on the 
hepatic retention of radioactivity was similar for anti-HER2 
and anti-IGF-1R affibody molecules, but the initial hepatic 
uptake of 99mTc-ZIGF1R:4551-GGGC was much higher. It is 
important to note that the hepatic uptake of radiolabeled 
ZIGF1R:4551 was not saturable neither in this, nor in previous 
studies using this construct, irrespective of the labels used 
(Tolmachev et al. 2012a; Orlova et al. 2013). Thus, hepatic 
uptake of 99mTc-ZIGF1R:4551-GGGC is, most likely, not-IGF-
1R specific. Furthermore, hepatic uptake was not associ-
ated with the affibody scaffold, as the hepatic uptake of the 
anti-HER2 99mTc-ZHER2:V2-GGGC affibody molecule with 
the same scaffold as ZIGF1R:4551 was much lower (Wåll-
berg et al. 2011). Therefore, the major difference in hepatic 
uptake between anti-HER2 and anti-IGF-1R affibody mol-
ecules is most likely a consequence of differences in their 
binding sites.
The binding site of ZIGF1R:4551 contains two glycines, 
two leucines, two serines, and one of each: phenylalanine, 
tyrosine, alanine, isoleucine, glutamine, lysine, and argi-
nine (Fig. 9). The binding site of the anti-HER2 ZHER2:V2 
affibody molecule contains three arginines, two tyrosines, 
and one of each: methionine, asparagine, tryptophan, ala-
nine, leucine, asparagine, glutamine, and lysine. A com-
parison of the lipophilicity using two different scales 
developed by Kyte and Doolittle (1982) and by Hopp and 
Woods (1981) suggests that the binding site of ZIGF1R:4551 
is appreciably more lipophilic than the binding site of 
ZHER2:V2, which may be the reason for the differences in 
hepatic uptake. This hypothesis is supported by previous 
findings that elevated hepatic uptake of proteins and pep-
tides is often associated with the presence of “hydrophobic 
patches” on their surface (Hosseinimehr et al. 2012). More-
over, we have found earlier that the hepatic uptake of anti-
HER2 affibody molecules correlated with the hydrophobic-
ity of the binding site (Tolmachev et al. 2012b).
The use of the peptide chelator HEHEHE at the N-ter-
minus led to a decrease in local hydrophobicity and sig-
nificant suppression of hepatic uptake of [99mTc(CO)3]+-
(HE)3-ZIGF1R:4551. The use of AEN-sequence at N-terminus 
of Z IGF1R:4551-GGGC is insufficient for this purpose, and 
the high initial hepatic uptake of 99mTc-ZIGF1R:4551-GGGC 
cannot be compensated by the quick release of radioactivity 
from liver that results from the non-residualizing properties 
of the 99mTc-GGGC label. A combination of a hydrophilic 
Fig. 9  Sequence comparison between the anti-IGF-1R affibody molecule ZIGF1R:4551-GGGC and anti-HER2-affibody molecule ZHER2:V2-GGGC. 
Amino acids in the binding site are boxed
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tag at the N-terminus and a non-residualizing label at C-ter-
minus might be a possible solution. However, we earlier 
evaluated a HEHEHE-ZHER2:342-GGGC format for labeling 
of anti-HER2 affibody molecule with 99mTc. It turned out, 
unfortunately, that 99mTc is also chelated by HEHEHE-tag, 
and the site specificity of labeling is lost (Lindberg et al. 
2012). Other approaches for increasing the hydrophilicity of 
the affibody molecules are therefore desirable to evaluate.
In conclusion, 99mTc-ZIGF1R:4551-GGGC allowed suc-
cessful visualization of IGF-1R expression in vivo, show-
ing a fast clearance of radioactivity from blood and normal 
organs and a remarkably low kidney retention. However, 
its potential in molecular imaging is limited by the high 
uptake of radioactivity in the liver that might obscure detec-
tion of hepatic metastases. The elevated hepatic uptake 
may be associated with the relatively hydrophobic binding 
site. This factor should be taken into account in molecular 
design of affibody molecules and other scaffold proteins.
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